SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of…Read More
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2 2023 Allogene Therapeutics NASDAQALLO
